Arthritis Therapeutics Market (Type: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Gout, and Others; Drug Class: TNF Inhibitors, Interleukin Inhibitors, NSAIDs, Corticosteroids, Xanthine Oxidase Inhibitors, and Others; Route of Administration: Oral, Parenteral, and Topical; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Arthritis Therapeutics Market: Numerous Product and Novel Drug Launches Leading to New Heights

The arthritis therapeutics market, characterized by healthy growth, is witnessing numerous promising pipeline projects and new product launches in parallel to increasing awareness campaigns run by public and private organizations. The patent expiration of blockbuster drugs is putting more pressure on manufacturers to develop effective versions of these drugs, which is projected to pave the way for the advancements of biosimilar products.

According to the Centers for Disease Control and Prevention (CDC) data published in 2018, ~54 Mn adults in the U.S. have been diagnosed with arthritis, and the number will grow to ~78 Mn by 2040. In this fast-paced era, individuals can’t afford to reduce their range of motion, which pertinently entails that those residing in developed countries are massively partaking in the diagnosis and treatment of arthritis as compared to those in developing countries. In the future, as the success of health awareness campaigns increases in developing countries, manufacturers in the arthritis therapeutics market will scramble towards these countries to leverage the first mover’s advantage.

Perpetual Increase in Drug Prices to Impact Health of Arthritis Therapeutics Market

Despite the stronghold of disease-modifying antirheumatic drugs (DMARDs) in the arthritis therapeutics market, next gen antibody therapeutics are found to gain ground in recent times, on account of their higher efficiency. However, the efficiency of these drugs comes at a price, indeed a high one, ranging from US$ 1,000 to US$ 3,000 per month, which could hold back the sales potential of these drugs.

The price of Humira - a default drug for the treatment of arthritis - saw a steep increase in its price by 68.7% over the last five years, which equals to US$ 3,700 for a month-long supply. Also, the wholesale cost of the drug Enbrel has risen by 80.3% in the same time period, as found by Alliance of Community Health Plans. What’s more of an adoption concern for patients is the lack of discounts and deals, and the retail price further rises when they are distributed to retailers and pharmacies. Given the recommendation for a long-term course of arthritis treatment, high cost can affect the monthly budgets of patients, which could negatively impact sales in the arthritis therapeutics market space.

Parenteral Route to Grow as Preferable Drug-consumption Mode

As per the report, in 2019, the parenteral route of drug administration is projected to be used for ~83% cases for arthritis treatment, while in the remaining ~17% cases, the oral and topical route will be preferred. To put this data into perspective, parenteral administration possesses better control over the dose and frequency, thereby ensuring an improved treatment outcome as compared to oral therapeutics. These routes of drug administration, in turn, are also found to offer better bioavailability and metabolism avoidance. On the contrary, patients are liable to maintain a course of oral drugs on their own, and in cases where they miss out on popping a pill, recovery can take a longer time.

Analysts’ Opinion on Arthritis Therapeutics Market

Analysts of the report opine that, the arthritis therapeutics market will record 8.5% more sales in 2019 over 2018, and continue to advance at a CAGR of ~6% during 2019-2027. The high prevalence of arthritis that primarily weakens the joints and degrades the quality of life of patients, is projected to encourage more patients to avail proper treatment options. Given the growing demand, head-to-head trails to boost the efficacy profiles of drugs intensify the competition in the arthritis therapeutics market, and strategic partnership to target new markets backed by innovative product-level approaches will form a profitable deal for manufacturers.

It is worth noting that, retail pharmacies will take over ~78% sales of these therapeutics in the year 2019, which implies the need for market players to strengthen distribution partnerships with retailers of all scales.

Global Arthritis Therapeutics Market: Overview

The global arthritis therapeutics market was valued at ~US$ 43 Bn in 2018, and is projected to expand at a CAGR of ~6% from 2019 to 2027, to reach ~US$ 72.6 Bn by 2027.

Increasing incidence of arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and other types of arthritis across the globe, is a major factor that is likely to fuel the global arthritis therapeutics market.

Ongoing arthritis clinical trials, increase in the geriatric population, rising investments in research & development, increasing demand for biologics, launching of novel products, and surge in mergers and strategic alliances are also anticipated to propel the growth of the global market.

Arthritis is an inflammatory joint condition, which causes pain and stiffness, and worsens with age. More than 100 types of arthritis exists, along with different causes and underlying infections. The common types of arthritis are rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.

Several therapeutics and medications have been developed in recent years to relieve and treat the symptoms of arthritis. The most commonly used drugs belong to the drug class of TNF inhibitors, interleukin inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and other drugs. TNF inhibitors are widely utilized for the treatment of arthritis disorders. Arthritis is a highly underdiagnosed and undertreated medical condition, with a large number of patients unsatisfied with the current treatment options available. This offers significant opportunity to biopharmaceutical players operating in the arthritis therapeutics market to offer novel drugs. The under-penetration of biologic drugs in a majority of developed and emerging markets for the treatment of arthritis offers significant opportunities to global biopharmaceutical players.

A large number of both, small molecules and biologic products are under different phases of clinical trials. Leading companies have made significant investments in clinical R&D, and have established strategic partnerships and collaborations to accelerate new product development.

Global Arthritis Therapeutics Market: Key Segment

Based on type, the global arthritis therapeutics market has been categorized into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, gout, and others. Among these, the rheumatoid arthritis segment is the largest, and is expected to dominate the market during the forecast period. The high market share of the rheumatoid arthritis segment can be attributed to the availability of effective biologics for its treatment. The psoriatic arthritis segment is projected to grow at the highest pace during the forecast period, due to increasing number of psoriasis patients likely to develop psoriatic arthritis.

In terms of drug class, the global arthritis therapeutics market has been divided into TNF inhibitors, interleukin inhibitors, NSAIDs, corticosteroids, xanthine oxidase inhibitors, and others. The TNF inhibitors segment dominates the global market, owing to its higher efficacy rate as compared to other small molecules. Moreover, increasing investments toward the development of TNF inhibitor biologics are likely to drive the segment. The interleukin inhibitors segment is expected to expand at the highest CAGR, owing to ongoing clinical studies supporting their effectiveness, and quick adoption of interleukin inhibitors in gout, PsA, and RA indications.

On the basis of route of administration, the global arthritis therapeutics market has been segmented into oral, parenteral, and topical. The parenteral segment accounted for the largest share of the global market, and is expected to continue its dominance, owing to large volume prescriptions of biologic drugs administered through intravenous and subcutaneous injections.

Based on distribution channel, the global market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment holds a major market share, owing to the easy availability of biologics drugs in retail pharmacies, and increasing retail pharmacy stores across the globe.

Global Arthritis Therapeutics Market: Major Players

Key players operating in the global arthritis therapeutics market include

• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc
• Janssen Global Services
• LLC (Johnson & Johnson)
• F. Hoffmann-La Roche Ltd
• Sanofi.

These players are focused on mergers & acquisitions, development of novel products, launch of biosimilars, and implementation of inorganic and inorganic growth strategies to strengthen their product portfolios and global footprint.

Moreover, companies are attracting investments for the research & development of arthritis drugs in order to improve patient care and remain competitive in the global market.

Key Questions Answered in the Arthritis Therapeutics Market Report

• How does the recent launching of novel and effective drugs provide scope of growth in the global market?
• How are ongoing clinical trials for arthritis widening the scope for arthritis therapeutics?
• How are various drug classes effective in the treatment of arthritis, and provide opportunities to key players for growth?
• What are the revenue share projections of key segments under various criteria in the global market for the forecast period?
• Which segment is likely to lead the market in terms of revenue by 2027?
• How are changing regulatory scenarios, along with changing healthcare systems in developed and developing countries having an impact on the overall market?

Global Arthritis Therapeutics Market – Segmentation 

Type

• Rheumatoid Arthritis
• Osteoarthritis
• Psoriatic Arthritis
• Gout
• Others

Drug Class

• TNF Inhibitors
• Interleukin Inhibitors
• NSAIDs
• Corticosteroids
• Xanthine Oxidase Inhibitors
• Others

Route of Administration

• Oral
• Parenteral
• Topical

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North
• America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4.  Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Arthritis Therapeutics Market

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Arthritis Therapeutics Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Key product/brand Analysis

    5.2. Pipeline Analysis

    5.3. Disease Prevalence & Incidence Rate globally with key countries

    5.4. Regulatory Scenario by Region/globally

6. Global Arthritis Therapeutics Market Analysis and Forecast, By Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Type, 2017–2027

        6.3.1. Rheumatoid Arthritis

        6.3.2. Osteoarthritis

        6.3.3. Psoriatic Arthritis

        6.3.4. Gout

        6.3.5. Others

    6.4. Market Attractiveness By Type

7. Global Arthritis Therapeutics Market Analysis and Forecast, By Drug Class 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        7.3.1. TNF Inhibitors

        7.3.2. Interleukin Inhibitors

        7.3.3. NSAIDs

        7.3.4. Corticosteroids

        7.3.5. Xanthine Oxidase Inhibitors

        7.3.6. Others

    7.4. Market Attractiveness By Drug Class 

8. Global Arthritis Therapeutics Market Analysis and Forecast, By Route of Administration 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        8.3.1. Oral

        8.3.2. Parenteral

        8.3.3. Topical 

    8.4. Market Attractiveness By Route of Administration 

9. Global Arthritis Therapeutics Market Analysis and Forecast, By Distribution Channel 

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness By Distribution Channel

10. Global Arthritis Therapeutics Market Analysis and Forecast, By Region 

    10.1. Key Findings

    10.2. Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Region

        10.2.1. North America

        10.2.2. Europe 

        10.2.3. Asia Pacific

        10.2.4. Latin America 

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness By Country/Sub-region /Region

11. North America Arthritis Therapeutics Market Analysis and Forecast

    11.1.  Introduction

        11.1.1.  Key Findings

    11.2. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        11.2.1. Rheumatoid Arthritis

        11.2.2. Osteoarthritis

        11.2.3. Psoriatic Arthritis

        11.2.4. Gout

        11.2.5. Others

    11.3.  North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        11.3.1. TNF Inhibitors

        11.3.2. Interleukin Inhibitors

        11.3.3. NSAIDs

        11.3.4. Corticosteroids

        11.3.5. Xanthine Oxidase Inhibitors

        11.3.6. Others

    11.4.  North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        11.4.1. Oral

        11.4.2. Parenteral

        11.4.3. Topical 

    11.5. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        11.5.1. Hospital Pharmacies

        11.5.2. Retail Pharmacies

        11.5.3. Online Pharmacies

    11.6. North America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Market Attractiveness Analysis

        11.7.1. By Type

        11.7.2. By Drug Class

        11.7.3. By Route of Administration

        11.7.4. By Distribution Channel

        11.7.5. By Country/Sub-region 

12. Europe Arthritis Therapeutics Market Analysis and Forecast

    12.1.  Introduction

        12.1.1.  Key Findings

    12.2. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        12.2.1. Rheumatoid Arthritis

        12.2.2. Osteoarthritis

        12.2.3. Psoriatic Arthritis

        12.2.4. Gout

        12.2.5. Others

    12.3.  Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        12.3.1. TNF Inhibitors

        12.3.2. Interleukin Inhibitors

        12.3.3. NSAIDs

        12.3.4. Corticosteroids

        12.3.5. Xanthine Oxidase Inhibitors

        12.3.6. Others

    12.4.  Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        12.4.1. Oral

        12.4.2. Parenteral

        12.4.3. Topical 

    12.5. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        12.5.1. Hospital Pharmacies

        12.5.2. Retail Pharmacies

        12.5.3. Online Pharmacies

    12.6. Europe Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Country/Sub-region, 2017–2027

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Market Attractiveness Analysis

        12.7.1. By Type

        12.7.2. By Drug Class

        12.7.3. By Route of Administration

        12.7.4. By Distribution Channel

        12.7.5. By Country/Sub-region 

13. Asia Pacific Arthritis Therapeutics Market Analysis and Forecast

    13.1.  Introduction

        13.1.1.  Key Findings

    13.2. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        13.2.1. Rheumatoid Arthritis

        13.2.2. Osteoarthritis

        13.2.3. Psoriatic Arthritis

        13.2.4. Gout

        13.2.5. Others

    13.3.  Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        13.3.1. TNF Inhibitors

        13.3.2. Interleukin Inhibitors

        13.3.3. NSAIDs

        13.3.4. Corticosteroids

        13.3.5. Xanthine Oxidase Inhibitors

        13.3.6. Others

    13.4.  Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        13.4.1. Oral

        13.4.2. Parenteral

        13.4.3. Topical 

    13.5. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        13.5.1. Hospital Pharmacies

        13.5.2. Retail Pharmacies

        13.5.3. Online Pharmacies

    13.6. Asia Pacific Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Market Attractiveness Analysis

        13.7.1. By Type

        13.7.2. By Drug Class

        13.7.3. By Route of Administration

        13.7.4. By Distribution Channel

        13.7.5. By Country/Sub-region 

14. Latin America Arthritis Therapeutics Market Analysis and Forecast

    14.1.  Introduction

        14.1.1.  Key Findings

    14.2. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        14.2.1. Rheumatoid Arthritis

        14.2.2. Osteoarthritis

        14.2.3. Psoriatic Arthritis

        14.2.4. Gout

        14.2.5. Others

    14.3. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        14.3.1. TNF Inhibitors

        14.3.2. Interleukin Inhibitors

        14.3.3. NSAIDs

        14.3.4. Corticosteroids

        14.3.5. Xanthine Oxidase Inhibitors

        14.3.6. Others

    14.4.  Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        14.4.1. Oral

        14.4.2. Parenteral

        14.4.3. Topical 

    14.5. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        14.5.1. Hospital Pharmacies

        14.5.2. Retail Pharmacies

        14.5.3. Online Pharmacies

    14.6. Latin America Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region /Sub-region, 2017–2027

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Market Attractiveness Analysis

        14.7.1. By Type

        14.7.2. By Drug Class

        14.7.3. By Route of Administration

        14.7.4. By Distribution Channel

        14.7.5. By Country/Sub-region 

15. Middle East & Africa Arthritis Therapeutics Market Analysis and Forecast

    15.1.  Introduction

        15.1.1.  Key Findings

    15.2. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Type, 2017–2027

        15.2.1. Rheumatoid Arthritis

        15.2.2. Osteoarthritis

        15.2.3. Psoriatic Arthritis

        15.2.4. Gout

        15.2.5. Others

    15.3.  Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Drug Class, 2017–2027

        15.3.1. TNF Inhibitors

        15.3.2. Interleukin Inhibitors

        15.3.3. NSAIDs

        15.3.4. Corticosteroids

        15.3.5. Xanthine Oxidase Inhibitors

        15.3.6. Others

    15.4.  Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Route of Administration, 2017–2027

        15.4.1. Oral

        15.4.2. Parenteral

        15.4.3. Topical 

    15.5. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, by  Distribution Channel, 2017–2027

        15.5.1. Hospital Pharmacies

        15.5.2. Retail Pharmacies

        15.5.3. Online Pharmacies

    15.6. Middle East & Africa Arthritis Therapeutics Market Value (US$ Mn) Forecast, By Country/Sub-region , 2017–2027

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Market Attractiveness Analysis

        15.7.1. By Type

        15.7.2. By Drug Class

        15.7.3. By Route of Administration

        15.7.4. By Distribution Channel

        15.7.5. By Country/Sub-region 

16. Competition Landscape

    16.1. Market Share Analysis By Company (2018)

    16.2.  Company Profiles

        16.2.1. Novartis AG

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Financial Overview      

            16.2.1.3. Product Portfolio

            16.2.1.4. Strategic Overview

            16.2.1.5. SWOT Analysis

        16.2.2. Eli Lilly and Company

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Financial Overview      

            16.2.2.3. Product Portfolio

            16.2.2.4. Strategic Overview

            16.2.2.5. SWOT Analysis

        16.2.3. Amgen, Inc.

            16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.3.2. Financial Overview      

            16.2.3.3. Product Portfolio

            16.2.3.4. Strategic Overview

            16.2.3.5. SWOT Analysis

        16.2.4. Merck & Co., Inc.

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Financial Overview      

            16.2.4.3. Product Portfolio

            16.2.4.4. Strategic Overview

            16.2.4.5. SWOT Analysis

        16.2.5. Bristol-Myers Squibb Company

            16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.5.2. Financial Overview      

            16.2.5.3. Product Portfolio

            16.2.5.4. Strategic Overview

            16.2.5.5. SWOT Analysis

        16.2.6. Pfizer, Inc. 

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Financial Overview      

            16.2.6.3. Product Portfolio

            16.2.6.4. Strategic Overview

            16.2.6.5. SWOT Analysis

        16.2.7. AbbVie, Inc.

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Financial Overview      

            16.2.7.3. Product Portfolio

            16.2.7.4. Strategic Overview

            16.2.7.5. SWOT Analysis

        16.2.8. Janssen Global Services, LLC (Johnson & Johnson)

            16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.8.2. Financial Overview      

            16.2.8.3. Product Portfolio

            16.2.8.4. Strategic Overview

            16.2.8.5. SWOT Analysis

        16.2.9. F. Hoffmann-La Roche Ltd

            16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.9.2. Financial Overview      

            16.2.9.3. Product Portfolio

            16.2.9.4. Strategic Overview

            16.2.9.5. SWOT Analysis

        16.2.10. Sanofi

            16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.10.2. Financial Overview      

            16.2.10.3. Product Portfolio

            16.2.10.4. Strategic Overview

            16.2.10.5. SWOT Analysis